PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis

American Journal of Pathology

Volumn 159, Issue 1, 2001, Pages 359-367

  Sasaki, Hikaru ^a   Zlatescu, Magdalena C ^c   Betensky, Rebecca A ^b   Ino, Yasushi ^a   Cairncross, J Gregory ^c   Louis, David N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; DMBT1 PROTEIN, HUMAN; ERCC6 PROTEIN, HUMAN; HELICASE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PTEN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CHROMOSOME 10; CHROMOSOME MAP; GENE DELETION; GENETICS; HOMOZYGOTE; HUMAN; MUTATION; OLIGODENDROGLIOMA; PHYSIOLOGY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

AGGLUTININS; ANTINEOPLASTIC AGENTS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 10; DNA HELICASES; DNA REPAIR ENZYMES; GENE DELETION; HOMOZYGOTE; HUMANS; MUTATION; OLIGODENDROGLIOMA; PHOSPHORIC MONOESTER HYDROLASES; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 0035406063     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)61702-6     Document Type: Article

References (54)

1. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997, 79:1381-1393
2. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma Ann Neurol 1988, 23:360-364
3. Cairncross G, Macdonald D, Ludwin S, Lee D Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold CJ: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994, 12:2013-2021
4. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1997, 90:1473-1479
5. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997, 57:4183-4186
6. Rasheed BK, Stenzel TT, Mclendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH: PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 1997, 57: 4187-4190
7. Schmidt EE, Ichimura K, Goike HM, Moshref A, Liu L, Collins VP: Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J Neuropathol Exp Neurol 1999, 58:1170-1183
8. Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP: Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosom Cancer 1998, 22: 9-15
9. Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL, Wu X, Chan W, Pershouse MA, Yung WK, Steck PA: Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res 1998, 4:2447-2454
10. Bigner SH, Matthews MR Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, Mclendon RE, Bigner DD: Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999, 155:375-386
11. Rasheed BK, Mclendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, Bigner SH: Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 1995, 10: 2243-2246
12. Albarosa R, Colombo BM, Roz L, Magnani I, Polio B, Cirenel N, Giani C, Conti AM, DiDonato S, Finocchiaro G: Deletion mapping of gliomas suggests the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am J Hum Genet 1996, 58:1260-1267
13. Maier D, Comparone D, Taylor E, Zhang Z, Gratzl O, Van Meir EG, Scott RJ, Merlo A: New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. Oncogene 1997, 15:997-1000
14. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947
15. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV: Identfication of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362
16. Li DM, Sun H: TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β. Cancer Res 1997, 57:2124-2129
17. Zhou XP, Li YJ, Hoang-Xuan K, Laurent-Puig P, Mokhtari K, Longy M Sanson M, Delattre JY, Thomas G, Hamelin R: Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 1999, 84:150-154
18. Cantley L, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/Akt pathway Proc Natl Acad Sci USA 1999, 96:4240-4245
19. Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell 2000, 100:387-390
20. Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M: PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis, Oncogene 1999, 18:3936-3943
21. Bostrom J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P, Collins VP, Reifenberger G: Mutation of the PTEM (MMACD tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 1998, 58:29-33
22. Okami K, Wu L, Riggins G, Cairns P, Goggins M, Evron E, Halachmi N, Ahrendt SA, Reed AL, Hilgers W, Kern SE, Koch WM, Sidransky D, Jen J: Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 1998, 58:509-511
23. Mollenhauer J, Herbertz S, Holmskov U, Tolnay M, Krebs I, Merlo A, Schroder HD, Maier D, Breitling F, Wiemann S, Grone HJ, Poustka A: DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer. Cancer Res 2000, 60:1704-1710
24. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgen bus KK, von Deimling A, Poustka A: DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet 1997, 17:32-39
25. Somerville RP, Shoshan Y, Eng C, Barnett G, Miller D, Cowell JK: Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression. Oncogene 1998, 17:1755-1757
26. Wu W, Kemp BL, Proctor ML, Gazdar AF, Minna JD, Hong WK, Mao L: Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer. Cancer Res 1999, 59:1846-1851
27. Mori M, Shiraishi T, Tanaka S, Yamagata M, Mafune K, Tanaka Y, Ueo H, Barnard GF, Sugimachi K: Lack of DMBT1 expression in oesophageal, gastric and colon cancers. Br J Cancer 1999, 79:211-213
28. Mollenhauer J, Holmskov U, Wiemann S, Krebs I, Herbertz S, Madsen J, Kioschis P, Coy JF, Poustka A: The genomic structure of the DMBT1 gene: evidence for a region with susceptibility to genomic instability. Oncogene 1999, 18:6233-6240
29. Troelstra C, Landsvater RM, Wiegant J, van der Ploeg M, Viel G, Buys CH, Hoeijmakers JH: Localization of the nucleotide excision repair gene ERCC6 to human chromosome 10q11-q21. Genomics 1992, 12:745-749
30. Troelstra C, van Gool A, de Wit J, Vermeulen W, Bootsma D, Hoeijmakers JH ERCC6, a member of a subfamily of putative helicase, is involved in Cockayne's syndrome and preferential repair of active genes. Cell 1992, 71:939-953
31. Selby CP, Sancar A: Human transcription-repair coupling factor CSB/ ERCC6 is a DNA-stimulated ATPase but is not a helicase and does not disrupt the ternary transcription complex of stalled RNA polymerase II. J Biol Chem 1997, 272:1885-1890
32. Jaeckle KA, Zhang L, Lee PSY, Connor T, Ali-Osman F: ERCC6 mutations in human malignant astrocytomas. Neuro-Oncology 1999, 1:317
33. Louis DN, Gusella JF: A tiger behind many doors: multiple genetic pathways to malignant gliomas. Trends Genet 1995, 11:412-415
34. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP: Oligodendroglial tumors and mixed gliomas. World Health Organization Classification of Tumours of the Central Nervous System. Edited by P Kleihues, WK Cavenee. Lyon, IARC/WHO, 2000, pp 55-70
35. Louis DN, von Deimling A, Seizinger BR: A (CA)n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens. Am J Pathol 1992, 141:777-782
36. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997, 57: 4997-5000
37. Ueki K, Rubio MP, Ramesh V, Correa KM, Rutter JL, von Deimling A, Buckler AJ, Gusella JF, Louis DN: MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 1994, 3:1841-1845
38. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A: PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998, 16:2259-2264
39. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WKA, Fujii G, Berson A, Bookstein R, Bolen JB, Tavtigian SV, Steck PA: MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997, 57:5221-5225
40. Dahia PL, FitzGeratd MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, von Deimling A, Haluska FG, Haber DA, Eng C: A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene 1998, 16:2403-2406
41. Ono Y Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K, Louis DN: Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 1996, 55:1026-1031
42. Ino Y, Betensky R, Zlatescu M, Sasaki H, Macdonald D, Stemmer-Rachamimov A, Ramsay D, Caincross J, Louis D: Molecular subtypes of anaplastic oligodendroglioma implications for patient management at diagnosis Clin Cancer Res 2001, 7:839-845
43. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwap D, Sidransky D: Frequency of homozygous deletion at p16/ CDKN2 in primary human tumours. Nat Genet 1995, 11:210-212
44. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP: Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999, 99:323-334
45. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, Grossman HB: MMAC1/PTEN inhibits cell growth and induces chemosensitivlty to doxorubicin in human bladder cancer cells Oncogene 2000, 19: 5406-5412
46. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A: PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998 4:3005-3010
47. Raffel C, Frederick L, O'Fallon JR, Atherton-Skaff P, Perry A, Jenkins RB, James CD: Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 1999, 5:4085-4090
48. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR Myers JN, Hong YK, Yung WK, Steck PA: Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to ocalization and prognosis. Cancer Res 1999, 59:1820-1824
49. Jallal B, Powell J, Zacnwieja J, Brakebusch C, Germain L, Jacobs J Iacobelli S, Ullrich A: Suppression of tumor growth in vivo by local and systemic 90K level increase. Cancer Res 1995, 55:3223-3227
50. Mallery DL, Tanganell B, Colella S, Steingrimsdottir H, van Gool AJ, Troelstra C, Stefanini M, Lehmann AR: Molecular analysis of mutations in the CSB (ERCC6) gene in patients with Cockayne syndrome Am J Hum Genet 1998, 62:77-85
51. Colella S, Nardo T, Mallery D, Borrone C, Ricci R, Ruffa G, Lehmann AR, Stefanini M: Alterations in the CSB gene in tnree Italian patients with the severe form of cockayne syndrome (CS) but without clinical photosensitivity. Hum Mol Genet 1999, 8:935-941
52. van der Horst GT, van Steeg H, Berg RJ, van Gool AJ de Wit J, Weeda G, Morreau H, Beems RB, van Kreijl CF, de Gruijl FR, Bootsma D, Hoeijmakers JH: Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition Cell 1997, 89:425-435
53. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O'Fallon J, Yates A, Feuerstein BG, Burger PC Scheithauer BW, Jenkins RB: Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999, 18 4144-4152
54. den Dunnen JT, Antonarakis SE: Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000, 15:7-12